TwitterFacebookInstagramPinterestYouTubeTumblrRedditWhatsAppThreads

Improving Cancer Care: Potential for Enhanced Immunotherapy Treatment Identified

Improving Cancer Care: Potential for Enhanced Immunotherapy Treatment Identified

Improving Cancer Care: Potential for Enhanced Immunotherapy Treatment Identified

A breakthrough study by Brigham and Women’s Hospital researchers suggests that by revising existing cancer care protocols, an estimated 6,000 more cancer patients in the United States annually could benefit from immunotherapy treatment.

The study, published in Cancer Cell, revealed that the current standard diagnostic test for mismatch repair deficiency, immunohistochemistry, missed detecting nearly 6% of endometrial cancer and 1% of colorectal cancer patients with this condition. These overlooked cases could potentially be identified through next-generation sequencing, thus expanding the pool of patients eligible for immunotherapy.

Dr. Elias Bou Farhat, the study’s first author, emphasized the significance: “Patients with mismatch repair deficiency respond remarkably to immunotherapy, even in advanced cancer stages, sometimes achieving long-term remission or even potential cure.”

Colorectal and endometrial cancers commonly exhibit high rates of mismatch repair deficiency, impairing DNA repair and leading to cancer. Immunotherapy, leveraging the body’s immune system, has shown promising results in these patients. However, the study highlighted that immunohistochemistry, the current standard test, may miss crucial cases identified by next-generation sequencing.

The research analyzed 1,655 patients from Brigham and Women’s Hospital and Dana-Farber Cancer Institute, finding that patients identified as mismatch repair deficient via sequencing but missed by immunohistochemistry showed similar positive responses to immunotherapy. This suggests the need for a more sensitive diagnostic tool like next-generation sequencing.

Dr. Amin Nassar, the study’s senior author, underscored the importance of accurate diagnoses to avoid ineffective or potentially harmful treatments, stressing the importance of providing suitable therapies.

While the findings propose next-generation sequencing as a more sensitive diagnostic method, further research is essential for validation and broad application. The study also highlighted better treatment outcomes for patients receiving immunotherapy compared to those who did not, emphasizing the criticality of identifying candidates for this treatment.

Future research aims to explore wider applicability in different cancer types and additional genetic deficiencies linked to mismatch repair deficiency, ultimately seeking to enhance cancer care through precise and effective treatment approaches.

VoM News Desk
VoM News Desk

VoM News is an online web portal in jammu Kashmir offers regional, National & global news.

Scroll to Top